Proteomics

Dataset Information

0

Quantitative secretomics identifies ligand-receptor pairs in pancreatic cancer that mediate bidirectional crosstalk between cancer stem cells and nociceptors


ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest and most metastatic cancers in human. PDACs respond poorly to therapies, partly due to cancer stem cells (CSCs) that self-renew, survive chemotherapies, metastasise and replenish the tumour. Factors secreted by tumour cells mediate autocrine/paracrine crosstalk with surrounding cells contributing to the stem cell niche but are still insufficiently characterised. Here we used quantitative SILAC proteomics to identify secreted factors enriched in CSC secretome compared to non-CSCs. Among them were GDF15 and VGF, factors involved in cachexia and pain stimuli. GDF15 and VGF promoted CSC self-renewal and growth through autocrine effects. TGFβ/Activin signalling lowered GDF15 and VGF expression via SMAD2/3-SMAD4-SNON, switching to ATF4-CREB-mediated induction upon cell stress. Co-culture of PDAC-CSCs and hESC-derived neural cells for mimicking cellular crosstalk in PDAC revealed that paracrine signalling via GDF15/VGF promoted nociceptor formation and neurite outgrowth. In turn, Substance P from neurons supported CSC self-renewal, EMT/migration and clonal evolution that was also impacted by SMAD4 genetic status. Lastly, the serum levels of GDF15 and VGF were elevated in PDAC patients suggesting their utility as biomarkers for PDAC detection. Collectively, our data uncovered that cachexia and pain signalling factors mediate the crosstalk between CSCs and nociceptors.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Pancreatic Ductal Adenocarcinoma Cell Line

DISEASE(S): Pancreatic Ductal Adenocarcinoma

SUBMITTER: Svenja Hester  

LAB HEAD: Dr. Siim Pauklin

PROVIDER: PXD046026 | Pride | 2024-04-06

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2015-11-01 | E-MTAB-3808 | biostudies-arrayexpress
2024-02-18 | GSE244326 | GEO
2024-02-18 | GSE244287 | GEO
| 2169532 | ecrin-mdr-crc
2017-04-12 | GSE80241 | GEO
2020-06-25 | PXD018585 | Pride
2024-09-30 | GSE222985 | GEO
2024-09-30 | GSE222983 | GEO
2024-01-01 | GSE222952 | GEO
2023-01-09 | PXD034037 | Pride